Alloy Therapeutics Signs Collaboration And License Agreement With Takeda To Develop Takeda's Proprietary Induced Pluripotent Stem Cell Derived CAR-T Cell Platform And IPSC-Derived CAR-NK Platform
Alloy Therapeutics Signs Collaboration And License Agreement With Takeda To Develop Takeda's Proprietary Induced Pluripotent Stem Cell Derived CAR-T Cell Platform And IPSC-Derived CAR-NK Platform
Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK) to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies.
合金治疗公司（"合金"）是一家生物技术生态系统公司，致力于使尖端药物发现科技的使用更加普及。今天，合金宣布与武田制药有限公司（纽交所：TAK）达成战略合作和许可协议，以开发武田的专有诱导性多能干细胞（iPSC）衍生的CAR-T细胞平台（iCAR-T）和iPSC衍生的CAR-NK平台（iCAR-NK）。合金将专注于加速关键疗法的开发，以克服实体肿瘤和血液恶性肿瘤。
iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at Kyoto University. The core technology to differentiate iPSC into immune cells originates from CiRA's Shin Kaneko's laboratory. iCAR-T has potential to develop 'off-the-shelf' cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy.
iCAR-T科技是在武田和京都大学iPS研究与应用中心（CiRA）之间的t-CiRA联合研究计划中开发的。将iPSC分化为免疫细胞的核心技术源自CiRA的金信实验室。iCAR-T有潜力开发“即用型”的细胞疗法，提供最佳性能的潜力，具有增强的效力，并且与自体细胞疗法相比，大大降低制造成本。
热门市场机会
热门讨论
热门讨论
